EUCTR2019-001488-60-DE进行中（未招募）1 期
A randomized, controlled, open-label, phase-III trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) high risk, HR+/HER2- early breast cancer. - ADAPTlate
Westdeutsche Studiengruppe GmbH0 个研究点目标入组 1,700 人开始时间: 2020年5月25日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,700
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. Written informed consent prior to any study procedures (outcomes of standard-of-care procedures performed before signing of informed consent by the patient but within the allowed screening period can be used for patient screening).
- •3.= 18 years of age.
- •4a.EITHER: (Post)menopausal status at the time of initiation of adjuvant study medication
- •patient underwent bilateral oophorectomy, or
- •age = 60, or
- •age < 60 and amenorrhea for 12 or more months (in the absence of chemotherapy, tamoxifen, or ovarian suppression) and/or FSH and estradiol in the postmenopausal range per local normal range.
- •4b.OR: Pre-menopausal patients:
- •confirmed negative serum or urine pregnancy test (ß-hCG) before starting study treatment, or
- •patient has had a hysterectomy.
- •5.Histologically confirmed diagnosis of primary estrogen-receptor positive and/or progesterone-receptor positive (>1%) early breast cancer by local laboratory. In case the receptor status from local pathology is unclear a central pathology review is obligatory. Results must be known prior to randomization.
- •6. Patient has HER2-negative breast cancer defined as
- •a negative in-situ hybridization test or an IHC status of 0, 1+, or 2+,
- •if IHC is 2+, a negative in-situ hybridization (FISH, CISH, or SISH) test is required (based on the analyzed tissue sample at initial diagnosis by a local laboratory).
- •7.Patients are eligible
- •with completed (i.e., 5 years according to SoC), planned or ongoing adjuvant endocrine therapy, without any signs of distant relapse or secondary malignancy AND
- •if primary diagnosis was 6 years or less before enrollment
- •8a. Known high clinical risk, in case of neoadjuvant chemotherapy, defined as either one of the following criteria: see protocol
- •Known high clinical risk, in case of adjuvant treatment (chemotherapy and/or ET), defined as either one of the following criteria: see protocol
- •8b. Known high genomic risk, defined as either one of the following criteria: see protocol
- •NOTE: In case of neoadjuvant chemotherapy treatment: participation of non-pCR patients is strongly recommended
- •In case the tumor is of intermediate clinical risk, but genomic risk is not known at registration:
- •8c.Intermediate clinical and unknown genomic risk,
- •c or yp/pN 0 with luminal-B-like tumor (G3 and/or Ki-67 pre-treatment = 20%) or c or yp/pN 1, AND (see protocol)
- •NOTE: In case of neoadjuvant chemotherapy treatment: participation of non-pCR patients is strongly recommended
- •8d Patients after isolated locoregional relapse with high-risk patterns (e.g., T2-3 or N1-3 or G3 or Ki-67 pre-treatment = 20%), once surgery with free margins was completed
- •Inclusion is only possible for the first locoregional relapse removed by surgery (free margins)
- •9. Completed primary therapy of breast cancer according to current guidelines, i.e., after (neo)adjuvant treatment, definite surgery and radiotherapy, if applicable.
- •10.No clinical evidence of distant metastasis (confirmation recommended prior to randomization by either combination of or either one of the following examinations: CT thorax / abdomen, chest X-ray, liver ultrasound, bone scan, PET-CT).
- •11.Patient has available tumor tissue from primary diagnostic biopsy.
- •12.No contraindication for adjuvant ET.
- •13.Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- •14.Patient has adequate bone marrow and organ function as defined by the following laboratory values: see protocol
- •15.Ability to swallow abe
排除标准
- •Patients eligible for inclusion in this study must not meet any of the following criteria:
- •1. Patient with distant metastases of breast cancer beyond regional lymph nodes.
- •2.Previously received CDK 4/6 inhibitor or patient with an indication for abemaciclib in the clinical routine per respective country:
- •N 1 and at least one of the following criteria: G3 or T3 and
- •<14 months after primary diagnosis
- •3. Patient with a known hypersensitivity to any of the excipients of abemaciclib or standard-of-care endocrine therapy.
- •4. Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects.
- •5. Patient has not recovered from clinical and laboratory acute toxicities related to prior anticancer therapies to NCI CTCAE version 5.0 Grade = 1 (polyneuropathy = 2 or residual alopecia is allowed).
- •6. Patient has a concurrent malignancy or non-breast malignancy within 5 years prior to randomization.
- •7. Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs (e.g., uncontrolled ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small-bowel resection).
- •8. Patient has any active systemic bacterial infection (requiring intravenous antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C [for example, hepatitis B surface antigen positive]. Screening is not required for enrollment.
- •9. Patient has any other concurrent severe and/or uncontrolled medical condition that, in the investigator´s judgment, could cause unacceptable safety risks, contraindicate patient participation in the clinical study, or compromise compliance with the protocol (e.g., interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment [e.g. estimated creatinine clearance <30ml/min], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn’s disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea, etc.).
- •10. Patient has a personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest.
- •11. Patient is currently receiving any of the following substances, which cannot be discontinued 7 days prior to day 1 of study treatment:
- •- concomitant medications and herbal supplements, that are strong inducers or inhibitors of CYP3A4.
- •12. Participation in a prior investigational study within 30 days prior to enrollment..
- •13. Not able to understand and to comply with study instructions and requirements.
- •14. Pregnant or nursing (lactating) woman.
- •15. Woman of child-bearing potential defined as woman physiologically capable of becoming pregnant, unless she is using highly effective methods of contraception during the study treatment and for 21 days after stopping the treatment:
- •a. total abstinence (when this is in line with the preferred and usual lifestyle of the patient),
- •b. female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least 6 weeks before taking study treatment,
- •c. male partner s
研究者
相似试验
招募中
1 期
A randomized, controlled, open-label, phase III-trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) intermediate to high risk, HR+/HER2- early breast cancer (ADAPTlate)HR+/HER2- early breast cancerMedDRA version: 23.0Level: PTClassification code: 10083234Term: Hormone receptor positive breast cancer Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10057654Term: Breast cancer female Class: 100000004864MedDRA version: 23.0Level: PTClassification code: 10083232Term: HER2 negative breast cancer Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10006187Term: Breast cancer Class: 100000004864CTIS2023-509242-35-00WSG Westdeutsche Studiengruppe GmbH2,000
招募中
3 期
Study of efficacy of capmatinib in comparison with standard of care docetaxel as a second or third line therapy in participants with non-small cell lung cancers harboring MET exon 14 skipping mutation.CTRI/2020/09/027575ovartis Healthcare Pvt Ltd
进行中（未招募）
1 期
Study of efficacy of capmatinib in comparison with standard of care docetaxel as a second or third line therapy in participants with non-small cell lung cancers harboring MET exon 14 skipping mutation.EUCTR2020-001578-31-NLovartis Pharma AG90
已完成
3 期
A phase III, randomized, controlled, open-label, multicenter, global study of capmatinib versus SoC docetaxel chemotherapy in previously treated patients with EGFR wt, ALK negative, locally advanced or metastatic (stage IIIB/IIIC or IV) NSCLC harboring MET exon 14 skipping mutation (MET*ex14)non small cell lung cancer with a C-MET mutation10038666NL-OMON52922ovartis4
进行中（未招募）
1 期
Study of efficacy of capmatinib in comparison with standard of care docetaxel as a second or third line therapy in participants with non-small cell lung cancers harboring MET exon 14 skipping mutation.cMET mutated NSCLCMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-001578-31-FRovartis Pharma AG90